Tolebrutinib, a BTK inhibitor, demonstrated a 31% delay in confirmed disability progression for nrSPMS in a phase 3 study.

Tolebrutinib, a BTK inhibitor, showed a 31% delay in confirmed disability progression for non-relapsing secondary progressive multiple sclerosis (nrSPMS) in a phase 3 study, presented at the ECTRIMS conference. Additionally, it nearly doubled the rate of confirmed disability improvement compared to placebo. It also delayed worsening in relapsing multiple sclerosis but without statistical significance. Regulatory submissions for the drug are anticipated in late 2024.